Elan Company Description
Elan has brains on its mind. The company is focused on the development of pharmaceuticals for neurological and autoimmune diseases, as well as for severe pain and infection. Its product offerings include anti-infectives Maxipime and Azactam and severe chronic pain infusion Prialt. Elan's future fortunes rely largely on the success of beleaguered multiple sclerosis (MS) therapy Tysabri, which it co-developed with Biogen Idec. Elan's pipeline of potential future releases includes drugs for the treatment of Alzheimer's disease and Parkinson's disease. Its Elan Drug Technologies unit provides specialty drug development using its oral time-release technology to improve the delivery of drugs.
View the Comprehensive Company Description for Elan
The Company Description provides a historical perspective of Elan's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Elan's evolution in the marketplace.
